New York State Common Retirement Fund Has $46.94 Million Stock Holdings in Vericel Co. (NASDAQ:VCEL)

New York State Common Retirement Fund decreased its position in shares of Vericel Co. (NASDAQ:VCEL) by 0.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 854,902 shares of the biotechnology company’s stock after selling 7,762 shares during the period. New York State Common Retirement Fund owned about 1.73% of Vericel worth $46,943,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in VCEL. International Assets Investment Management LLC boosted its position in shares of Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 619 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 322 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Vericel in the third quarter valued at approximately $92,000. Finally, Geneos Wealth Management Inc. boosted its position in Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,240 shares in the last quarter.

Insider Buying and Selling

In other Vericel news, insider Jonathan Siegal sold 3,908 shares of Vericel stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total value of $242,256.92. Following the completion of the sale, the insider now directly owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. The trade was a 76.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jonathan Mark Hopper sold 10,000 shares of Vericel stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $58.72, for a total transaction of $587,200.00. Following the completion of the sale, the insider now directly owns 58,371 shares of the company’s stock, valued at approximately $3,427,545.12. This trade represents a 14.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,600 shares of company stock valued at $1,356,072 over the last quarter. Insiders own 7.20% of the company’s stock.

Vericel Stock Up 0.9 %

Shares of NASDAQ VCEL opened at $57.78 on Thursday. Vericel Co. has a twelve month low of $39.12 and a twelve month high of $63.00. The firm has a fifty day simple moving average of $57.81 and a 200 day simple moving average of $51.48. The company has a market capitalization of $2.85 billion, a PE ratio of 963.16 and a beta of 1.72.

Wall Street Analyst Weigh In

VCEL has been the topic of a number of research analyst reports. Truist Financial raised their target price on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. BTIG Research raised their target price on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Canaccord Genuity Group lifted their price target on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Stephens reiterated an “overweight” rating and set a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. Finally, StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Vericel currently has an average rating of “Moderate Buy” and an average target price of $63.14.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.